<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Cancer Sci</journal-id>
    <journal-id journal-id-type="iso-abbrev">Cancer Sci</journal-id>
    <journal-id journal-id-type="doi">10.1111/(ISSN)1349-7006</journal-id>
    <journal-id journal-id-type="publisher-id">CAS</journal-id>
    <journal-title-group>
      <journal-title>Cancer Science</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1347-9032</issn>
    <issn pub-type="epub">1349-7006</issn>
    <publisher>
      <publisher-name>John Wiley and Sons Inc.</publisher-name>
      <publisher-loc>Hoboken</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7648030</article-id>
    <article-id pub-id-type="pmid">32810311</article-id>
    <article-id pub-id-type="doi">10.1111/cas.14621</article-id>
    <article-id pub-id-type="publisher-id">CAS14621</article-id>
    <article-categories>
      <subj-group subj-group-type="overline">
        <subject>Original Article</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Original Articles</subject>
        <subj-group subj-group-type="heading">
          <subject>Basic and Clinical Immunology</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>A novel scoring method based on RNA‐Seq immunograms describing individual cancer‐immunity interactions</article-title>
      <alt-title alt-title-type="left-running-head">KOBAYASHI et al.</alt-title>
    </title-group>
    <contrib-group>
      <contrib id="cas14621-cr-0001" contrib-type="author">
        <name>
          <surname>Kobayashi</surname>
          <given-names>Yukari</given-names>
        </name>
        <xref ref-type="aff" rid="cas14621-aff-0001">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="cas14621-aff-0002">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib id="cas14621-cr-0002" contrib-type="author">
        <name>
          <surname>Kushihara</surname>
          <given-names>Yoshihiro</given-names>
        </name>
        <xref ref-type="aff" rid="cas14621-aff-0001">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib id="cas14621-cr-0003" contrib-type="author">
        <name>
          <surname>Saito</surname>
          <given-names>Noriyuki</given-names>
        </name>
        <xref ref-type="aff" rid="cas14621-aff-0001">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib id="cas14621-cr-0004" contrib-type="author">
        <name>
          <surname>Yamaguchi</surname>
          <given-names>Shigeo</given-names>
        </name>
        <xref ref-type="aff" rid="cas14621-aff-0003">
          <sup>3</sup>
        </xref>
        <xref ref-type="aff" rid="cas14621-aff-0004">
          <sup>4</sup>
        </xref>
      </contrib>
      <contrib id="cas14621-cr-0005" contrib-type="author" corresp="yes">
        <name>
          <surname>Kakimi</surname>
          <given-names>Kazuhiro</given-names>
        </name>
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2631-3040</contrib-id>
        <xref ref-type="aff" rid="cas14621-aff-0001">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="cas14621-aff-0002">
          <sup>2</sup>
        </xref>
        <address>
          <email>kakimi@m.u-tokyo.ac.jp</email>
        </address>
      </contrib>
    </contrib-group>
    <aff id="cas14621-aff-0001">
      <label>
        <sup>1</sup>
      </label>
      <named-content content-type="organisation-division">Department of Immunotherapeutics</named-content>
      <institution>The University of Tokyo Hospital</institution>
      <city>Tokyo</city>
      <country country="JP">Japan</country>
    </aff>
    <aff id="cas14621-aff-0002">
      <label>
        <sup>2</sup>
      </label>
      <named-content content-type="organisation-division">Cancer Immunology Data Multi‐level Integration Unit</named-content>
      <named-content content-type="organisation-division">Medical Science Innovation Hub Program</named-content>
      <institution>RIKEN</institution>
      <city>Tokyo</city>
      <country country="JP">Japan</country>
    </aff>
    <aff id="cas14621-aff-0003">
      <label>
        <sup>3</sup>
      </label>
      <named-content content-type="organisation-division">Department of Surgery</named-content>
      <institution>Keio University School of Medicine</institution>
      <city>Tokyo</city>
      <country country="JP">Japan</country>
    </aff>
    <aff id="cas14621-aff-0004">
      <label>
        <sup>4</sup>
      </label>
      <institution>cBioinformatics</institution>
      <city>Tokyo</city>
      <country country="JP">Japan</country>
    </aff>
    <author-notes>
      <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Kazuhiro Kakimi, Department of Immunotherapeutics, The University of Tokyo Hospital, 7‐3‐1 Hongo, Bunkyo‐Ku, Tokyo 113‐8655, Japan.<break/>
Email: <email>kakimi@m.u-tokyo.ac.jp</email><break/></corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>09</day>
      <month>9</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <month>11</month>
      <year>2020</year>
    </pub-date>
    <volume>111</volume>
    <issue>11</issue>
    <issue-id pub-id-type="doi">10.1111/cas.v111.11</issue-id>
    <fpage>4031</fpage>
    <lpage>4040</lpage>
    <history>
      <date date-type="received">
        <day>16</day>
        <month>7</month>
        <year>2020</year>
      </date>
      <date date-type="rev-recd">
        <day>13</day>
        <month>8</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>14</day>
        <month>8</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 Japanese Cancer Association <copyright-statement>-->
      <copyright-statement content-type="article-copyright">© 2020 The Authors. <italic>Cancer Science</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association</copyright-statement>
      <license license-type="creativeCommonsBy-nc-nd">
        <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="file:CAS-111-4031.pdf"/>
    <abstract id="cas14621-abs-0001">
      <title>Abstract</title>
      <p>Because of the complexity of cancer‐immune system interactions, combinations of biomarkers will be required for predicting individual patient responses to treatment and for monitoring combination strategies to overcome treatment resistance. To this end, the “immunogram” has been proposed as a comprehensive framework to capture all relevant immunological variables. Here, we developed a method to convert transcriptomic data into immunogram scores (IGS). This immunogram includes 10 molecular profiles, consisting of innate immunity, priming and activation, T cell response, interferon γ (IFNG) response, inhibitory molecules, regulatory T cells, myeloid‐derived suppressor cells (MDSCs), recognition of tumor cells, proliferation, and glycolysis. Using genes related to these 10 parameters, we applied single‐sample gene set enrichment analysis (ssGSEA) to 9417 bulk RNA‐Seq data from 9362 cancer patients with 29 different solid cancers in The Cancer Genome Atlas (TCGA). Enrichment scores were z‐score normalized (Z) for each cancer type or the entire TCGA cohort. The IGS was defined by the formula <italic>IGS = 3 + 1.5 × Z</italic> so that patients would be well distributed over a range of scores from 1 to 5. The immunograms constructed in this way for all individual patients in the entire TCGA cohort can be accessed at “The RNA‐Seq based Cancer Immunogram Web” (<ext-link ext-link-type="uri" xlink:href="https://yamashige33.shinyapps.io/immunogram/">https://yamashige33.shinyapps.io/immunogram/</ext-link>).</p>
    </abstract>
    <abstract abstract-type="graphical" id="cas14621-abs-0002">
      <p>We propose a novel scoring and visualization method for “immunogram” to assess the cancer immunity status of individual patients using the large TCGA dataset and RNA‐Seq of each patient. Immunograms for each individual will be a useful tool for precision immuno‐oncology, although their application needs to be validated in clinical trials.<boxed-text position="anchor" content-type="graphic" id="cas14621-blkfxd-0001" orientation="portrait"><graphic xlink:href="CAS-111-4031-g006.jpg" position="anchor" id="nlm-graphic-1" orientation="portrait"/></boxed-text>
</p>
    </abstract>
    <kwd-group>
      <kwd id="cas14621-kwd-0001">GSEA</kwd>
      <kwd id="cas14621-kwd-0002">immunogram</kwd>
      <kwd id="cas14621-kwd-0003">RNA‐Seq</kwd>
      <kwd id="cas14621-kwd-0004">TCGA</kwd>
      <kwd id="cas14621-kwd-0005">tumor immunity</kwd>
    </kwd-group>
    <funding-group>
      <award-group id="funding-0001">
        <funding-source>
          <institution-wrap>
            <institution>RIKEN </institution>
            <institution-id institution-id-type="open-funder-registry">10.13039/501100006264</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <fig-count count="5"/>
      <table-count count="2"/>
      <page-count count="10"/>
      <word-count count="6102"/>
    </counts>
    <custom-meta-group>
      <custom-meta>
        <meta-name>source-schema-version-number</meta-name>
        <meta-value>2.0</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>cover-date</meta-name>
        <meta-value>November 2020</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>details-of-publishers-convertor</meta-name>
        <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.3 mode:remove_FC converted:06.11.2020</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
  <notes>
    <p content-type="self-citation">
      <mixed-citation publication-type="journal" id="cas14621-cit-1001"><string-name><surname>Kobayashi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kushihara</surname><given-names>Y</given-names></string-name>, <string-name><surname>Saito</surname><given-names>N</given-names></string-name>, <string-name><surname>Yamaguchi</surname><given-names>S</given-names></string-name>, <string-name><surname>Kakimi</surname><given-names>K</given-names></string-name>. <article-title>A novel scoring method based on RNA‐Seq immunograms describing individual cancer‐immunity interactions</article-title>. <source xml:lang="en">Cancer Sci</source>. <year>2020</year>;<volume>111</volume>:<fpage>4031</fpage>–<lpage>4040</lpage>. <pub-id pub-id-type="doi">10.1111/cas.14621</pub-id></mixed-citation>
    </p>
  </notes>
</front>
<body id="cas14621-body-0001">
  <def-list list-content="abbreviations" id="cas14621-lp-0001">
    <title>Abbreviations</title>
    <def-item>
      <term>ACC</term>
      <def>
        <p>adrenocortical carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>BLCA</term>
      <def>
        <p>bladder urothelial carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>BRCA</term>
      <def>
        <p>breast invasive carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>CESC</term>
      <def>
        <p>cervical squamous cell carcinoma and endocervical adenocarcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>CHOL</term>
      <def>
        <p>cholangiocarcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>COAD</term>
      <def>
        <p>colon adenocarcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>CTS</term>
      <def>
        <p>cancer type–specific</p>
      </def>
    </def-item>
    <def-item>
      <term>ESCA</term>
      <def>
        <p>esophageal carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>fpkm</term>
      <def>
        <p>fragments per kilobase of exon per million reads mapped</p>
      </def>
    </def-item>
    <def-item>
      <term>GBM</term>
      <def>
        <p>glioblastoma multiforme</p>
      </def>
    </def-item>
    <def-item>
      <term>HNSC</term>
      <def>
        <p>head and neck squamous cell carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>ICI</term>
      <def>
        <p>immune checkpoint inhibitors</p>
      </def>
    </def-item>
    <def-item>
      <term>IGS</term>
      <def>
        <p>immunogram scores</p>
      </def>
    </def-item>
    <def-item>
      <term>KICP</term>
      <def>
        <p>kidney chromophobe</p>
      </def>
    </def-item>
    <def-item>
      <term>KIRC</term>
      <def>
        <p>kidney renal clear cell carcinoma,</p>
      </def>
    </def-item>
    <def-item>
      <term>KIRP</term>
      <def>
        <p>kidney renal papillary cell carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>LGG</term>
      <def>
        <p>brain lower grade glioma</p>
      </def>
    </def-item>
    <def-item>
      <term>LIHC</term>
      <def>
        <p>liver hepatocellular carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>LUAD</term>
      <def>
        <p>lung adenocarcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>LUSC</term>
      <def>
        <p>lung squamous cell carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>MDSC</term>
      <def>
        <p>myeloid‐derived suppressor cell</p>
      </def>
    </def-item>
    <def-item>
      <term>MESO</term>
      <def>
        <p>mesothelioma</p>
      </def>
    </def-item>
    <def-item>
      <term>MSigDB</term>
      <def>
        <p>Molecular Signatures Database</p>
      </def>
    </def-item>
    <def-item>
      <term>OV</term>
      <def>
        <p>ovarian serous cystadenocarcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>PAAD</term>
      <def>
        <p>pancreatic adenocarcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>PAN</term>
      <def>
        <p>pan‐cancer</p>
      </def>
    </def-item>
    <def-item>
      <term>PCPG</term>
      <def>
        <p>pheochromocytoma and paraganglioma</p>
      </def>
    </def-item>
    <def-item>
      <term>PRAD</term>
      <def>
        <p>prostate adenocarcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>READ</term>
      <def>
        <p>rectum adenocarcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>SARC</term>
      <def>
        <p>sarcoma</p>
      </def>
    </def-item>
    <def-item>
      <term>SKCM</term>
      <def>
        <p>skin cutaneous melanoma</p>
      </def>
    </def-item>
    <def-item>
      <term>ssGSEA</term>
      <def>
        <p>single‐sample gene set enrichment analysis</p>
      </def>
    </def-item>
    <def-item>
      <term>STAD</term>
      <def>
        <p>stomach adenocarcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>TCGA</term>
      <def>
        <p>The Cancer Genome Atlas</p>
      </def>
    </def-item>
    <def-item>
      <term>THCA</term>
      <def>
        <p>thyroid carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>TME</term>
      <def>
        <p>tumor microenvironment</p>
      </def>
    </def-item>
    <def-item>
      <term>UCEC</term>
      <def>
        <p>uterine corpus endometrial carcinoma</p>
      </def>
    </def-item>
    <def-item>
      <term>UCS</term>
      <def>
        <p>uterine carcinosarcoma</p>
      </def>
    </def-item>
    <def-item>
      <term>UVM</term>
      <def>
        <p>uveal melanoma</p>
      </def>
    </def-item>
  </def-list>
  <sec id="cas14621-sec-0001">
    <label>1</label>
    <title>INTRODUCTION</title>
    <p>Immunotherapy with immune checkpoint inhibitors (ICIs) has completely changed the therapeutic landscape for many types of solid tumors.<xref rid="cas14621-bib-0001" ref-type="ref"><sup>1</sup></xref> Several combinations of immunotherapy with chemotherapy,<xref rid="cas14621-bib-0002" ref-type="ref"><sup>2</sup></xref>, <xref rid="cas14621-bib-0003" ref-type="ref"><sup>3</sup></xref>, <xref rid="cas14621-bib-0004" ref-type="ref"><sup>4</sup></xref> molecular targeted drugs,<xref rid="cas14621-bib-0005" ref-type="ref"><sup>5</sup></xref> or combinations of different ICIs<xref rid="cas14621-bib-0006" ref-type="ref"><sup>6</sup></xref>, <xref rid="cas14621-bib-0007" ref-type="ref"><sup>7</sup></xref> are now approved for the first‐line treatment of various cancers. However, not all types of cancer respond equally well to ICIs, and even in responsive cancers, only a subset of patients experiences durable responses and favorable long‐term outcomes. This is because primary and acquired resistance occurs in a considerable proportion of patients across different cancer types.<xref rid="cas14621-bib-0008" ref-type="ref"><sup>8</sup></xref>
</p>
    <p>Therefore, it is crucial to establish reliable predictive biomarkers to distinguish ICI responders from nonresponders, who may suffer unnecessary costs and toxicities, and to identify candidates for rational combination therapies.<xref rid="cas14621-bib-0009" ref-type="ref"><sup>9</sup></xref> Currently, tumor mutational burden<xref rid="cas14621-bib-0010" ref-type="ref"><sup>10</sup></xref>, <xref rid="cas14621-bib-0011" ref-type="ref"><sup>11</sup></xref>, <xref rid="cas14621-bib-0012" ref-type="ref"><sup>12</sup></xref> and PD‐L1 expression<xref rid="cas14621-bib-0013" ref-type="ref"><sup>13</sup></xref>, <xref rid="cas14621-bib-0014" ref-type="ref"><sup>14</sup></xref> are the two major variables used as biomarkers that have been validated in phase III clinical trials. Additionally, several other factors associated with response or resistance to ICIs across cancer types have been proposed as biomarkers, based on molecular profiling of cancers treated with different immunotherapies. These include an immune‐inflamed phenotype,<xref rid="cas14621-bib-0015" ref-type="ref"><sup>15</sup></xref>, <xref rid="cas14621-bib-0016" ref-type="ref"><sup>16</sup></xref> expression of T cell signaling pathway genes such as IFNγ,<xref rid="cas14621-bib-0017" ref-type="ref"><sup>17</sup></xref> microsatellite instability,<xref rid="cas14621-bib-0018" ref-type="ref"><sup>18</sup></xref> somatic copy‐number alterations,<xref rid="cas14621-bib-0019" ref-type="ref"><sup>19</sup></xref> human leukocyte antigen (HLA) class I diversity,<xref rid="cas14621-bib-0020" ref-type="ref"><sup>20</sup></xref> T cell repertoire clonality change,<xref rid="cas14621-bib-0021" ref-type="ref"><sup>21</sup></xref> WNT‐β‐catenin signaling,<xref rid="cas14621-bib-0022" ref-type="ref"><sup>22</sup></xref> TGFβ expression,<xref rid="cas14621-bib-0023" ref-type="ref"><sup>23</sup></xref> and even commensal microbiota.<xref rid="cas14621-bib-0024" ref-type="ref"><sup>24</sup></xref>
</p>
    <p>However, as single biomarkers, none of the above is sufficient to identify individual patients who will likely benefit from immunotherapy. Unlike conventional cancer therapies, immunotherapies, including ICIs, do not directly target tumor cells; instead, they affect tumor cells through the patient's immune system or the tumor microenvironment (TME).<xref rid="cas14621-bib-0025" ref-type="ref"><sup>25</sup></xref> Therefore, the different components that affect tumor‐immune interactions need to be taken into account when developing predictive biomarkers for immunotherapy. Comprehensive analysis of multiple different functional pathways and molecular networks that reveal integrated mechanisms of tumor‐immune interactions are crucial for this purpose. General and local cancer immunity status in each patient needs to be taken into consideration. To this end, Blank et al proposed the concept of the cancer immunogram that integrates multiparameter biomarkers to visualize the immunological status of an individual patient.<xref rid="cas14621-bib-0026" ref-type="ref"><sup>26</sup></xref> We have applied this concept to lung cancer patients and developed an immunogram reflecting the cancer‐immunity cycle.<xref rid="cas14621-bib-0027" ref-type="ref"><sup>27</sup></xref> Since then, van Dijk et al have reported an immunogram informative specifically for urothelial cancer patients.<xref rid="cas14621-bib-0028" ref-type="ref"><sup>28</sup></xref>
</p>
    <p>Although immunograms may be useful for visualizing the landscape of the tumor microenvironment and the compromised steps of antitumor immunity in each patient, both Blank et al and van Dijk et al had only theorized that they could be useful to patients but had not tested the concept in clinical practice. In contrast, we analyzed real‐world lung cancer patient data to generate immunograms with potential application for personalized immunotherapy. However, in the previous version of our immunogram, the parameters were normalized and scored within the cohort; this approach could, therefore, not be applied to other cohorts. Thus, in the present study, we utilized RNA‐Seq data from The Cancer Genome Atlas (TCGA) cohort as a standard and set up a scoring scale to quantify parameters incorporated in the immunogram. Here, we propose a novel versatile scoring method for constructing such individual immunograms.</p>
  </sec>
  <sec sec-type="materials-and-methods" id="cas14621-sec-0002">
    <label>2</label>
    <title>MATERIALS AND METHODS</title>
    <sec id="cas14621-sec-0003">
      <label>2.1</label>
      <title>Data and analysis</title>
      <p>RNA‐Seq data for 29 solid tumors from TCGA were downloaded via the Genomic Data Commons Data Portal (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>) (n = 9417). The dataset General Research Use in TCGA access as the project titled #12517: "Immunogram for personalized cancer immunotherapy" was approved by NIH (#49374‐7). For subjects with multiple RNA‐Seq data available, mean count data were converted into fragments per kilobase of exon per million reads mapped (fpkm) and used for gene set enrichment analysis (GSEA). RNA‐Seq data for 28 tumors from 27 melanoma patients who received anti‐PD‐1 treatment were obtained from Gene Expression Omnibus (Accession number: GSE78220).<xref rid="cas14621-bib-0029" ref-type="ref"><sup>29</sup></xref> The enrichment score is obtained using the single‐sample gene set enrichment analysis (ssGSEA) method<xref rid="cas14621-bib-0030" ref-type="ref"><sup>30</sup></xref> with R package ssGSEA 2.0 (<ext-link ext-link-type="uri" xlink:href="https://github.com/broadinstitute/ssGSEA2.0">https://github.com/broadinstitute/ssGSEA2.0</ext-link>) and R software version 3. 6. 0.</p>
    </sec>
    <sec sec-type="data-availability" id="cas14621-sec-0004">
      <label>2.2</label>
      <title>Availability of data and materials</title>
      <p>All data analyzed during this study are included in this published article and its <xref rid="cas14621-sup-0001" ref-type="supplementary-material">[Link]</xref>, <xref rid="cas14621-sup-0002" ref-type="supplementary-material">[Link]</xref>, <xref rid="cas14621-sup-0003" ref-type="supplementary-material">[Link]</xref>, <xref rid="cas14621-sup-0004" ref-type="supplementary-material">[Link]</xref> files. All data analyzed can be accessed at a web‐accessible database, “The RNA‐Seq based Cancer Immunogram Web” (<ext-link ext-link-type="uri" xlink:href="https://yamashige33.shinyapps.io/immunogram/">https://yamashige33.shinyapps.io/immunogram/</ext-link>).</p>
    </sec>
    <sec id="cas14621-sec-0005">
      <label>2.3</label>
      <title>Statistical analyses</title>
      <p>Spearman correlation coefficients between any pair of gene sets or axes for the immunogram were calculated. The results were interpreted according to the degree of association as strong (= 0.7‐1), moderate (= 0.5‐0.7), or low (&lt;0.5) after taking significant correlation (or) values into consideration. Hierarchical clustering (Ward's method) was performed using JMP Pro15.0.0 (SAS Institute Inc).</p>
    </sec>
  </sec>
  <sec sec-type="results" id="cas14621-sec-0006">
    <label>3</label>
    <title>RESULTS</title>
    <sec id="cas14621-sec-0007">
      <label>3.1</label>
      <title>Gene set selection for immunograms</title>
      <p>An immunogram is a flexible system to illustrate the immunological status of each patient by adopting any and all appropriate parameters. Here, we depict an immunogram on a radar plot with ten axes to provide a useful snapshot of the immune landscape in the tumor microenvironment of an individual patient (Figure <xref rid="cas14621-fig-0001" ref-type="fig">1</xref>). These ten molecular profiles are innate immunity: natural killer (NK) cells (axis 1), priming and activation: dendritic cells (DCs) (axis 2), T cells: CD8<sup>+</sup> T cell response (axis 3), interferon γ (IFNG) response (axis 4), inhibitory molecules (axis 5), inhibitory cells (regulatory T cells [Tregs], axis 6), inhibitory cells (myeloid‐derived suppressor cells [MDSCs], axis 7), recognition of tumor cells: antigen processing and presentation (axis 8), proliferation (axis 9), and glycolysis (axis 10). These pathways are all relevant for the development of antitumor immune responses. To quantify these molecular profiles, ssGSEA of bulk RNA‐Seq data was performed (Table <xref rid="cas14621-tbl-0001" ref-type="table">1</xref>, Table <xref rid="cas14621-sup-0003" ref-type="supplementary-material">S1</xref>).</p>
      <fig fig-type="Figure" xml:lang="en" id="cas14621-fig-0001" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Immunogram radar plots. To depict the molecular profiles of the tumor microenvironment in each patient, 10 parameters related to this process were scored and plotted on the radar plot. These consist of innate immunity (axis 1), priming and activation (axis 2), T cell response (axis 3), IFNG response (axis 4), inhibitory molecules (axis 5), regulatory T cells (Treg, axis 6), myeloid‐derived suppressor cells (MDSCs, axis 7), recognition of tumor cells and presentation (axis 8), proliferation (axis 9), and glycolysis (axis 10), all relevant for the development of antitumor immune responses</p>
        </caption>
        <graphic id="nlm-graphic-3" xlink:href="CAS-111-4031-g001"/>
      </fig>
      <table-wrap id="cas14621-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float">
        <label>Table 1</label>
        <caption>
          <p>Gene set for the 10‐axis immunogram</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <thead valign="top">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="top" rowspan="1" colspan="1">Axis</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Immunological parameter</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Gene set_name</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">1</td>
              <td align="left" rowspan="1" colspan="1">Innate immunity</td>
              <td align="left" rowspan="1" colspan="1">LM22 NK cells activated (31)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">2</td>
              <td align="left" rowspan="1" colspan="1">Priming &amp; activation</td>
              <td align="left" rowspan="1" colspan="1">LM22 Dendritic cells activated (31)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">3</td>
              <td align="left" rowspan="1" colspan="1">T cells</td>
              <td align="left" rowspan="1" colspan="1">LM22 T cells CD8 (31)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">4</td>
              <td align="left" rowspan="1" colspan="1">IFNG response</td>
              <td align="left" rowspan="1" colspan="1">HALLMARK INTERFERON GAMMA RESPONSE (MSigDB)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">5</td>
              <td align="left" rowspan="1" colspan="1">Inhibitory molecules</td>
              <td align="left" rowspan="1" colspan="1">Immune escape gene set (IEGS) immune escape (32)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">6</td>
              <td align="left" rowspan="1" colspan="1">Inhibitory cells (Tregs)</td>
              <td align="left" rowspan="1" colspan="1">LM22 T cells regulatory (Tregs) (31)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">7</td>
              <td align="left" rowspan="1" colspan="1">Inhibitory cells (MDSC)</td>
              <td align="left" rowspan="1" colspan="1">Angelova_MDSC (33)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">8</td>
              <td align="left" rowspan="1" colspan="1">Recognition of tumor cells</td>
              <td align="left" rowspan="1" colspan="1">REACTOME CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION (MSigDB)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">9</td>
              <td align="left" rowspan="1" colspan="1">Proliferation</td>
              <td align="left" rowspan="1" colspan="1">REACTOME DNA REPLICATION (MSigDB)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">10</td>
              <td align="left" rowspan="1" colspan="1">Glycolysis</td>
              <td align="left" rowspan="1" colspan="1">HALLMARK GLYCOLYSIS (MSigDB)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot id="cas14621-ntgp-0001">
          <title>Note</title>
          <fn id="cas14621-note-0001">
            <p>Molecular Signatures Database (MSigDB): https://www.gsea‐msigdb.org/gsea/msigdb/index.jsp.</p>
          </fn>
          <fn id="cas14621-note-0002">
            <p>Required marker genes for each axis are listed in Table <xref rid="cas14621-sup-0003" ref-type="supplementary-material">S1</xref>.</p>
          </fn>
        </table-wrap-foot>
        <permissions>
          <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
        </permissions>
      </table-wrap>
      <p>For the quantification of NK cells, DCs, CD8<sup>+</sup> T cells, and Tregs, gene sets from LM22 were utilized.<xref rid="cas14621-bib-0031" ref-type="ref"><sup>31</sup></xref> Gene sets for IFNG response, recognition of tumor cells: antigen processing and presentation, proliferation, and glycolysis were selected from the Molecular Signatures Database (MSigDB, <ext-link ext-link-type="uri" xlink:href="https://www.gsea-msigdb.org/gsea/msigdb/index.jsp">https://www.gsea‐msigdb.org/gsea/msigdb/index.jsp</ext-link>). Gene set for inhibitory molecules was utilized from immune escape gene set (IEGS) immune escape.<xref rid="cas14621-bib-0001" ref-type="ref"><sup>1</sup></xref>, <xref rid="cas14621-bib-0002" ref-type="ref"><sup>2</sup></xref>, <xref rid="cas14621-bib-0032" ref-type="ref"><sup>32</sup></xref> For MDSC, we followed the published gene set by Angelova et al.<xref rid="cas14621-bib-0033" ref-type="ref"><sup>33</sup></xref> We validated these selected gene sets by comparing them with similar gene sets available in the literature (Table <xref rid="cas14621-sup-0004" ref-type="supplementary-material">S2</xref>). As a test sample, we exploited the RNA‐Seq data of 103 melanoma patients from the TCGA and ran ssGSEA to obtain enrichment scores. For example, we compared 12 gene sets that are related to NK cells by Spearman correlation analysis to validate the gene set for axis 1 (Figure <xref rid="cas14621-fig-0002" ref-type="fig">2</xref>). Most gene sets showed a strong linear correlation with each other except the one reported by Şenbabaoğlu et al.<xref rid="cas14621-bib-0034" ref-type="ref"><sup>34</sup></xref> The LM22 NK cell gene set correlated well with the other gene sets. Similarly, gene sets for other axes were evaluated by Spearman correlation analysis, and their validity was confirmed (Figure. <xref rid="cas14621-sup-0001" ref-type="supplementary-material">S1</xref>).</p>
      <fig fig-type="Figure" xml:lang="en" id="cas14621-fig-0002" orientation="portrait" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Scatter plot matrix for Spearman correlation analysis of gene sets for axis 1. The RNA‐Seq data of 103 melanoma patients from The Cancer Genome Atlas (TCGA) were subjected to single‐sample gene set enrichment analysis (ssGSEA) with 12 gene sets related to innate immunity: Abbas_NK_cells,<xref rid="cas14621-bib-0039" ref-type="ref"><sup>39</sup></xref> Becht_NK_cells,<xref rid="cas14621-bib-0040" ref-type="ref"><sup>40</sup></xref> GO:0045087_innate_immune_response (AmiGo2), Huntington_NK_cells,<xref rid="cas14621-bib-0041" ref-type="ref"><sup>41</sup></xref> Angelova_NK_cells,<xref rid="cas14621-bib-0033" ref-type="ref"><sup>33</sup></xref> ImSig_NK_cells,<xref rid="cas14621-bib-0042" ref-type="ref"><sup>42</sup></xref> LM22_NK_cells_activated,<xref rid="cas14621-bib-0031" ref-type="ref"><sup>31</sup></xref> LM22_NK_activated_resting,<xref rid="cas14621-bib-0031" ref-type="ref"><sup>31</sup></xref> LM7_NK_cells,<xref rid="cas14621-bib-0043" ref-type="ref"><sup>43</sup></xref> Charoentong_NK_cells,<xref rid="cas14621-bib-0044" ref-type="ref"><sup>44</sup></xref> Schelker_NK_cells,<xref rid="cas14621-bib-0045" ref-type="ref"><sup>45</sup></xref> and Şenbabaoğlu_NK_cells.<xref rid="cas14621-bib-0034" ref-type="ref"><sup>34</sup></xref> The correlations of these gene sets were analyzed by Spearman correlation analysis. Pairwise correlation analyses of 12 gene sets are represented in the scatter plot matrix that contains all the pairwise data of ssGSEA scores with the indicated gene sets. The bivariate correlations for the dataset are shown with a color coding as follows: dark red is associated with Spearman correlation coefficient, <italic>R</italic>, equal to 1 and dark blue is associated with <italic>R</italic> = −1</p>
        </caption>
        <graphic id="nlm-graphic-5" xlink:href="CAS-111-4031-g002"/>
      </fig>
    </sec>
    <sec id="cas14621-sec-0008">
      <label>3.2</label>
      <title>Converting ssGSEA enrichment scores to immunogram scores</title>
      <p>To plot an immunogram, the scoring method depends on having reliable standard values for each axis. To this end, we utilized 9417 RNA‐Seq data from 9362 cancer patients with 29 different solid cancers in the TCGA dataset. These consist of breast invasive carcinoma (BRCA), uterine corpus endometrial carcinoma (UCEC), kidney renal clear cell carcinoma (KIRC), lung adenocarcinoma (LUAD), brain lower grade glioma (LGG), thyroid carcinoma (THCA), head and neck squamous cell carcinoma (HNSC), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), colon adenocarcinoma (COAD), bladder urothelial carcinoma (BLCA), stomach adenocarcinoma (STAD), ovarian serous cystadenocarcinoma (OV), liver hepatocellular carcinoma (LIHC), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), kidney renal papillary cell carcinoma (KIRP), sarcoma (SARC), pheochromocytoma and paraganglioma (PCPG), pancreatic adenocarcinoma (PAAD), rectum adenocarcinoma (READ), glioblastoma multiforme (GBM), esophageal carcinoma (ESCA), mesothelioma (MESO), uveal melanoma (UVM), kidney chromophobe (KICP), uterine carcinosarcoma (UCS), cholangiocarcinoma (CHOL), and adrenocortical carcinoma (ACC) (Table <xref rid="cas14621-tbl-0002" ref-type="table">2</xref>). The RNA‐Seq data were subjected to ssGSEA with the 10 gene sets mentioned above (Table <xref rid="cas14621-tbl-0001" ref-type="table">1</xref>).</p>
      <table-wrap id="cas14621-tbl-0002" xml:lang="en" content-type="Table" orientation="portrait" position="float">
        <label>Table 2</label>
        <caption>
          <p>Patients with 29 solid cancers from The Cancer Genome Atlas (TCGA)</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000" span="1"/>
          <thead valign="top">
            <tr style="border-bottom:solid 1px #000000">
              <th align="left" valign="top" rowspan="1" colspan="1">Cancer type</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Abbreviation</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Number of patients</th>
              <th align="left" valign="top" rowspan="1" colspan="1">Number of samples</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Breast invasive carcinoma</td>
              <td align="left" rowspan="1" colspan="1">BRCA</td>
              <td align="char" char="." rowspan="1" colspan="1">1091</td>
              <td align="char" char="." rowspan="1" colspan="1">1097</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Uterine corpus endometrial carcinoma</td>
              <td align="left" rowspan="1" colspan="1">UCEC</td>
              <td align="char" char="." rowspan="1" colspan="1">543</td>
              <td align="char" char="." rowspan="1" colspan="1">547</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Kidney renal clear cell carcinoma</td>
              <td align="left" rowspan="1" colspan="1">KIRC</td>
              <td align="char" char="." rowspan="1" colspan="1">530</td>
              <td align="char" char="." rowspan="1" colspan="1">534</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Lung adenocarcinoma</td>
              <td align="left" rowspan="1" colspan="1">LUAD</td>
              <td align="char" char="." rowspan="1" colspan="1">513</td>
              <td align="char" char="." rowspan="1" colspan="1">524</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Brain lower grade glioma</td>
              <td align="left" rowspan="1" colspan="1">LGG</td>
              <td align="char" char="." rowspan="1" colspan="1">511</td>
              <td align="char" char="." rowspan="1" colspan="1">511</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Thyroid carcinoma</td>
              <td align="left" rowspan="1" colspan="1">THCA</td>
              <td align="char" char="." rowspan="1" colspan="1">502</td>
              <td align="char" char="." rowspan="1" colspan="1">502</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Head and neck squamous cell carcinoma</td>
              <td align="left" rowspan="1" colspan="1">HNSC</td>
              <td align="char" char="." rowspan="1" colspan="1">500</td>
              <td align="char" char="." rowspan="1" colspan="1">500</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Lung squamous cell carcinoma</td>
              <td align="left" rowspan="1" colspan="1">LUSC</td>
              <td align="char" char="." rowspan="1" colspan="1">501</td>
              <td align="char" char="." rowspan="1" colspan="1">501</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Prostate adenocarcinoma</td>
              <td align="left" rowspan="1" colspan="1">PRAD</td>
              <td align="char" char="." rowspan="1" colspan="1">495</td>
              <td align="char" char="." rowspan="1" colspan="1">498</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Skin cutaneous melanoma</td>
              <td align="left" rowspan="1" colspan="1">SKCM</td>
              <td align="char" char="." rowspan="1" colspan="1">103</td>
              <td align="char" char="." rowspan="1" colspan="1">103</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Colon adenocarcinoma</td>
              <td align="left" rowspan="1" colspan="1">COAD</td>
              <td align="char" char="." rowspan="1" colspan="1">456</td>
              <td align="char" char="." rowspan="1" colspan="1">469</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Bladder urothelial carcinoma</td>
              <td align="left" rowspan="1" colspan="1">BLCA</td>
              <td align="char" char="." rowspan="1" colspan="1">408</td>
              <td align="char" char="." rowspan="1" colspan="1">412</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Stomach adenocarcinoma</td>
              <td align="left" rowspan="1" colspan="1">STAD</td>
              <td align="char" char="." rowspan="1" colspan="1">375</td>
              <td align="char" char="." rowspan="1" colspan="1">375</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Ovarian serous cystadenocarcinoma</td>
              <td align="left" rowspan="1" colspan="1">OV</td>
              <td align="char" char="." rowspan="1" colspan="1">374</td>
              <td align="char" char="." rowspan="1" colspan="1">374</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Liver hepatocellular carcinoma</td>
              <td align="left" rowspan="1" colspan="1">LIHC</td>
              <td align="char" char="." rowspan="1" colspan="1">371</td>
              <td align="char" char="." rowspan="1" colspan="1">371</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Cervical squamous cell carcinoma and endocervical adenocarcinoma</td>
              <td align="left" rowspan="1" colspan="1">CESC</td>
              <td align="char" char="." rowspan="1" colspan="1">304</td>
              <td align="char" char="." rowspan="1" colspan="1">304</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Kidney renal papillary cell carcinoma</td>
              <td align="left" rowspan="1" colspan="1">KIRP</td>
              <td align="char" char="." rowspan="1" colspan="1">288</td>
              <td align="char" char="." rowspan="1" colspan="1">288</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Sarcoma</td>
              <td align="left" rowspan="1" colspan="1">SARC</td>
              <td align="char" char="." rowspan="1" colspan="1">259</td>
              <td align="char" char="." rowspan="1" colspan="1">259</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Pheochromocytoma and paraganglioma</td>
              <td align="left" rowspan="1" colspan="1">PCPG</td>
              <td align="char" char="." rowspan="1" colspan="1">178</td>
              <td align="char" char="." rowspan="1" colspan="1">178</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Pancreatic adenocarcinoma</td>
              <td align="left" rowspan="1" colspan="1">PAAD</td>
              <td align="char" char="." rowspan="1" colspan="1">177</td>
              <td align="char" char="." rowspan="1" colspan="1">177</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Rectum adenocarcinoma</td>
              <td align="left" rowspan="1" colspan="1">READ</td>
              <td align="char" char="." rowspan="1" colspan="1">166</td>
              <td align="char" char="." rowspan="1" colspan="1">166</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Glioblastoma multiforme</td>
              <td align="left" rowspan="1" colspan="1">GBM</td>
              <td align="char" char="." rowspan="1" colspan="1">154</td>
              <td align="char" char="." rowspan="1" colspan="1">155</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Esophageal carcinoma</td>
              <td align="left" rowspan="1" colspan="1">ESCA</td>
              <td align="char" char="." rowspan="1" colspan="1">161</td>
              <td align="char" char="." rowspan="1" colspan="1">161</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Mesothelioma</td>
              <td align="left" rowspan="1" colspan="1">MESO</td>
              <td align="char" char="." rowspan="1" colspan="1">86</td>
              <td align="char" char="." rowspan="1" colspan="1">86</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Uveal melanoma</td>
              <td align="left" rowspan="1" colspan="1">UVM</td>
              <td align="char" char="." rowspan="1" colspan="1">80</td>
              <td align="char" char="." rowspan="1" colspan="1">80</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Kidney chromophobe</td>
              <td align="left" rowspan="1" colspan="1">KICH</td>
              <td align="char" char="." rowspan="1" colspan="1">65</td>
              <td align="char" char="." rowspan="1" colspan="1">65</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Uterine carcinosarcoma</td>
              <td align="left" rowspan="1" colspan="1">UCS</td>
              <td align="char" char="." rowspan="1" colspan="1">56</td>
              <td align="char" char="." rowspan="1" colspan="1">56</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Cholangiocarcinoma</td>
              <td align="left" rowspan="1" colspan="1">CHOL</td>
              <td align="char" char="." rowspan="1" colspan="1">36</td>
              <td align="char" char="." rowspan="1" colspan="1">45</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Adrenocortical carcinoma</td>
              <td align="left" rowspan="1" colspan="1">ACC</td>
              <td align="char" char="." rowspan="1" colspan="1">79</td>
              <td align="char" char="." rowspan="1" colspan="1">79</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1"/>
              <td align="left" rowspan="1" colspan="1">Total</td>
              <td align="char" char="." rowspan="1" colspan="1">9362</td>
              <td align="char" char="." rowspan="1" colspan="1">9417</td>
            </tr>
          </tbody>
        </table>
        <permissions>
          <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
        </permissions>
      </table-wrap>
      <p>For scoring the immunogram, z‐score normalization was applied to ssGSEA enrichment scores<sub>.</sub> Because of the considerable differences in gene expression profiles between cancer types, normalization was performed in subgroups of patients with each cancer type or in the entire TCGA cohort. Hence, we constructed two immunograms for each patient: a cancer type–specific (CTS) and a pan‐cancer (PAN) immunogram. The mean (M<sub>CTS</sub>) and standard deviation (SD<sub>CTS</sub>) values of the enrichment scores were calculated for subgroups of patients with each cancer type or the M<sub>PAN</sub> and SD<sub>PAN</sub> values of enrichment scores of all TCGA patients with 29 cancer types for pan‐cancer analysis. The enrichment score (ES<sub>n</sub>) of axis n in each patient was converted into z‐score Z<sub>CTS,</sub>
<italic><sub>n</sub></italic> or Z<sub>PAN,</sub>
<italic><sub>n</sub></italic> and then converted into the immunogram score IGS<sub>CTS,</sub>
<italic><sub>n</sub></italic> or IGS<sub>PAN,</sub>
<italic><sub>n</sub></italic> by the following formula.</p>
      <p>
        <disp-formula id="cas14621-disp-0001">
          <mml:math id="nlm-math-1">
            <mml:mrow>
              <mml:mtable>
                <mml:mtr>
                  <mml:mtd>
                    <mml:mrow>
                      <mml:msub>
                        <mml:mi>Z</mml:mi>
                        <mml:mrow>
                          <mml:mtext>CTS or PAN</mml:mtext>
                          <mml:mo>,</mml:mo>
                          <mml:mspace width="0.166667em"/>
                          <mml:mi>n</mml:mi>
                        </mml:mrow>
                      </mml:msub>
                      <mml:mo>=</mml:mo>
                      <mml:mspace width="0.166667em"/>
                      <mml:mfenced close=")" open="(" separators="">
                        <mml:mrow>
                          <mml:msub>
                            <mml:mtext>ES</mml:mtext>
                            <mml:mi>n</mml:mi>
                          </mml:msub>
                          <mml:mo>‐</mml:mo>
                          <mml:msub>
                            <mml:mi>M</mml:mi>
                            <mml:mrow>
                              <mml:mtext>CTS or PAN</mml:mtext>
                              <mml:mo>,</mml:mo>
                              <mml:mspace width="0.166667em"/>
                              <mml:mi>n</mml:mi>
                            </mml:mrow>
                          </mml:msub>
                        </mml:mrow>
                      </mml:mfenced>
                      <mml:mo stretchy="false">/</mml:mo>
                      <mml:msub>
                        <mml:mtext>SD</mml:mtext>
                        <mml:mrow>
                          <mml:mtext>CTS or PAN</mml:mtext>
                          <mml:mo>,</mml:mo>
                          <mml:mspace width="0.166667em"/>
                          <mml:mi>n</mml:mi>
                        </mml:mrow>
                      </mml:msub>
                    </mml:mrow>
                  </mml:mtd>
                </mml:mtr>
                <mml:mtr>
                  <mml:mtd>
                    <mml:mrow>
                      <mml:msub>
                        <mml:mtext>IGS</mml:mtext>
                        <mml:mrow>
                          <mml:mtext>CTS or PAN</mml:mtext>
                          <mml:mo>,</mml:mo>
                          <mml:mspace width="0.166667em"/>
                          <mml:mi>n</mml:mi>
                        </mml:mrow>
                      </mml:msub>
                      <mml:mo>=</mml:mo>
                      <mml:mspace width="0.166667em"/>
                      <mml:mn>3</mml:mn>
                      <mml:mo>+</mml:mo>
                      <mml:mspace width="0.166667em"/>
                      <mml:mn>1.5</mml:mn>
                      <mml:mo>×</mml:mo>
                      <mml:msub>
                        <mml:mi>Z</mml:mi>
                        <mml:mrow>
                          <mml:mtext>CTS or PAN</mml:mtext>
                          <mml:mo>,</mml:mo>
                          <mml:mspace width="0.166667em"/>
                          <mml:mi>n</mml:mi>
                        </mml:mrow>
                      </mml:msub>
                    </mml:mrow>
                  </mml:mtd>
                </mml:mtr>
                <mml:mtr>
                  <mml:mtd>
                    <mml:mrow>
                      <mml:mi>n</mml:mi>
                      <mml:mo>=</mml:mo>
                      <mml:mn>1</mml:mn>
                      <mml:mo>∼</mml:mo>
                      <mml:mn>10</mml:mn>
                    </mml:mrow>
                  </mml:mtd>
                </mml:mtr>
                <mml:mtr>
                  <mml:mtd>
                    <mml:mrow>
                      <mml:mtext>CTS</mml:mtext>
                      <mml:mspace width="0.166667em"/>
                      <mml:mo>=</mml:mo>
                      <mml:mrow>
                        <mml:mspace width="0.333333em"/>
                        <mml:mtext>BRCA, UCEC, KIRC, LUAD, LGG, THCA, HNSC, LUSC, PRAD, SKCM, COAD, BLCA, STAD, OV</mml:mtext>
                      </mml:mrow>
                      <mml:mo>,</mml:mo>
                      <mml:mspace width="0.166667em"/>
                      <mml:mi>L</mml:mi>
                      <mml:mi>I</mml:mi>
                      <mml:mi>H</mml:mi>
                      <mml:mi>C</mml:mi>
                      <mml:mo>,</mml:mo>
                      <mml:mspace width="0.166667em"/>
                      <mml:mi>C</mml:mi>
                      <mml:mi>E</mml:mi>
                      <mml:mi>S</mml:mi>
                      <mml:mi>C</mml:mi>
                      <mml:mo>,</mml:mo>
                      <mml:mspace width="0.166667em"/>
                      <mml:mi>K</mml:mi>
                      <mml:mi>I</mml:mi>
                      <mml:mi>R</mml:mi>
                      <mml:mi>P</mml:mi>
                      <mml:mo>,</mml:mo>
                      <mml:mspace width="0.166667em"/>
                      <mml:mi>S</mml:mi>
                      <mml:mi>A</mml:mi>
                      <mml:mi>R</mml:mi>
                      <mml:mi>C</mml:mi>
                      <mml:mo>,</mml:mo>
                      <mml:mspace width="0.166667em"/>
                      <mml:mi>P</mml:mi>
                      <mml:mi>C</mml:mi>
                      <mml:mi>P</mml:mi>
                      <mml:mi>G</mml:mi>
                      <mml:mo>,</mml:mo>
                      <mml:mspace width="0.166667em"/>
                      <mml:mi>P</mml:mi>
                      <mml:mi>A</mml:mi>
                      <mml:mi>A</mml:mi>
                      <mml:mi>D</mml:mi>
                      <mml:mo>,</mml:mo>
                      <mml:mspace width="0.166667em"/>
                      <mml:mi>R</mml:mi>
                      <mml:mi>E</mml:mi>
                      <mml:mi>A</mml:mi>
                      <mml:mi>D</mml:mi>
                      <mml:mo>,</mml:mo>
                      <mml:mspace width="0.166667em"/>
                    </mml:mrow>
                  </mml:mtd>
                </mml:mtr>
                <mml:mtr>
                  <mml:mtd>
                    <mml:mrow>
                      <mml:mtext>GBM, ESCA, MESO, UVM, KICH, UCS, CHOL, ACC</mml:mtext>
                    </mml:mrow>
                  </mml:mtd>
                </mml:mtr>
                <mml:mtr>
                  <mml:mtd/>
                </mml:mtr>
              </mml:mtable>
            </mml:mrow>
          </mml:math>
        </disp-formula>
      </p>
      <p>In each patient, IGSs for all axes were determined by these formulae and plotted onto the radar chart to generate cancer type–specific or pan‐cancer immunograms. The lower and upper limits of the IGS were set at 1 and 5. By definition, IGS = 3 represents an ES equivalent to the mean ES of the TCGA cohort, and IGS = 4.5 or IGS = 1.5 represents ES equivalent to the mean plus or minus one SD. The IGS was defined in this way so that patients would be well distributed over the range from 1 to 5. We then developed a web‐accessible database designated “The RNA‐Seq based Cancer Immunogram Web with the results of the 9362 cancer patients of the TCGA cohort (<ext-link ext-link-type="uri" xlink:href="https://yamashige33.shinyapps.io/immunogram/">https://yamashige33.shinyapps.io/immunogram/</ext-link>). Each patient has their own discrete immunogram, suggesting that the immune response and tumor microenvironment are unique to each individual.</p>
    </sec>
    <sec id="cas14621-sec-0009">
      <label>3.3</label>
      <title>Cancer type–specific and pan‐cancer immunograms</title>
      <p>As an example, immunograms (IG<sub>PAN</sub> and IG<sub>CTS</sub>) for one patient in the TCGA with LUAD, KIC, SKCM, BRCA, PRAD, or LGG are depicted in Figure <xref rid="cas14621-fig-0003" ref-type="fig">3</xref>. For each patient, the shapes of the cancer type–specific (IG<sub>CTS</sub>) and pan‐cancer (IG<sub>PAN</sub>) are different. Some tumors are rich in T cell infiltration and designated as “hot,” while “cold” tumors lack such infiltrations. In the pan‐cancer analysis, all the data from patients with hot and cold tumors are pooled. Therefore, M<sub>PAN</sub> is higher than M<sub>CTS</sub> for tumor types in which cold tumors are dominant. The opposite is true for hot tumor–dominant types. As shown in Figure <xref rid="cas14621-fig-0003" ref-type="fig">3</xref>, the outer areas of IG<sub>PAN</sub> for LUAD and KIRC are more extended than those of the corresponding IG<sub>CTS</sub>, suggesting that these tumors are immunologically hot. In contrast, the IG<sub>PAN</sub> for PRAD and LGG appear compressed relative to those of the corresponding IG<sub>CTS</sub>, suggesting that these tumors are immunologically cold. IG<sub>PAN</sub> is suitable for comparing immunological status across the different cancer types, whereas by using IG<sub>CTS</sub>, we can compare subtle individual differences in intratumoral immune responses between patients with the same types of cancer.</p>
      <fig fig-type="Figure" xml:lang="en" id="cas14621-fig-0003" orientation="portrait" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Pan‐cancer and cancer type–specific immunograms. In each patient, two immunograms can be depicted based on the different normalized scores, pan‐cancer and cancer type–specific. Immunograms for a randomly selected patient with LUAD (A), KIRC (B), SKCM (C), BRCA (D), PRAD (E), and LGG (F) from The Cancer Genome Atlas (TCGA) are shown. TCGA case ID is shown in the panel. 1. Innate immunity, 2. Priming &amp; activation, 3. T cells, 4. IFNG response, 5. Inhibitory molecules, 6. Inhibitory cells (Tregs), 7. Inhibitory cells (MDSCs), 8. Recognition of tumor cells, 9. Proliferation, 10. Glycolysis. BRCA, breast invasive carcinoma; KIRC, kidney renal clear cell carcinoma; LGG, brain lower grade glioma; LUAD, lung adenocarcinoma; PRAD, prostate adenocarcinoma; SKCM, skin cutaneous melanoma</p>
        </caption>
        <graphic id="nlm-graphic-7" xlink:href="CAS-111-4031-g003"/>
      </fig>
    </sec>
    <sec id="cas14621-sec-0010">
      <label>3.4</label>
      <title>A general overview of immune responses in each cancer type</title>
      <p>To gain a general overview of cancer type–specific immune responses in the tumor, we created fictional patients representing the 29 cancer types in the TCGA cohort by providing M<sub>CTS,</sub>
<italic><sub>n</sub></italic> for their ES<italic><sub>n</sub></italic>. When we depict IG<sub>CTS</sub> in these fictional patients, all immunograms show regular decagons with all axes equal to point 3.0. IG<sub>PANs</sub> for these patients are shown in Figure <xref rid="cas14621-fig-0004" ref-type="fig">4</xref>. Hierarchical clustering of these “patients” by their IGSs indicated that MESO, LUAD, KIRC, PAAD, LUSC, CESC, and HNSC are quite immunogenic, while UCS, GBM, ACC, PRAD, KICH, PCPG, UVM, and LGG are immunologically quiescent. These results are consistent with clinical experience as reflected in the approval of checkpoint inhibitors for these immunogenic cancer types (with the exception of PAAD).</p>
      <fig fig-type="Figure" xml:lang="en" id="cas14621-fig-0004" orientation="portrait" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Pan‐cancer immunograms for fictional patients with 29 solid cancers. A, Pan‐cancer immunograms were generated for 29 fictional patients with the mean enrichment scores of the corresponding cancer type. B, Hierarchical clustering with Ward's method of these patients using the10 immunogram scores. Data are shown with a color coding as follows: dark red is associated with an immunogram score (IGS) equal to 5 and dark blue is associated with IGS = 1</p>
        </caption>
        <graphic id="nlm-graphic-9" xlink:href="CAS-111-4031-g004"/>
      </fig>
    </sec>
    <sec id="cas14621-sec-0011">
      <label>3.5</label>
      <title>Immunograms for personalized immuno‐oncology</title>
      <p>Axes 1‐4 represent the series of dynamic processes involved in the induction of antitumor immune responses, and axis 8 is essential for the T cell recognition of tumor cells, whereas genes related to axes 5‐7 are seen as inhibitory counter‐regulators. Therefore, these axes often move together. To examine the correlation between all 10 axes of the immunogram, all IGS<sub>PANs</sub> of the 9417 patients were subjected to Spearman correlation analysis. As shown in Figure <xref rid="cas14621-fig-0005" ref-type="fig">5A</xref>, correlation coefficients among axes 1‐6 were &gt;0.7. These results could be interpreted to imply that selecting only one parameter within axes 1‐6 would be sufficient for incorporation into the immunogram. This might be so if we evaluate the immune response as a whole. However, this might also be misleading if these parameters are not redundant and required for the evaluation of each patient's immunological status. Examples of lung cancer patients shown in Figure <xref rid="cas14621-fig-0005" ref-type="fig">5</xref> demonstrate that each axis behaves differently. In the case of TCGA‐86‐8671‐01A, axes 1‐7 were equally high (Figure <xref rid="cas14621-fig-0005" ref-type="fig">5B</xref>), but in TCGA‐86‐8359‐01A, axes 1 and 3 were high, but axes 2, 4, and 5 were low. Axes 1, 3, and 6 were low and axes 2, 4, and 5 were high in TCGA‐97‐8175‐01A. The other three patients display additional different immunogram patterns. These results indicate that all these parameters are required to understand the antitumor immunity specifically in every single patient because combination immunotherapy could be selected to target each of the different detected impaired processes identified by the detailed immunogram.</p>
      <fig fig-type="Figure" xml:lang="en" id="cas14621-fig-0005" orientation="portrait" position="float">
        <label>Figure 5</label>
        <caption>
          <p>Immunograms for individual patients. A, Immunogram scores of each axis from 9417 patients’ data were subjected to Spearman correlation analysis. Pairwise correlation analyses of each axis of the immunogram are represented in the heatmap matrix that contains all the pairwise data of the indicated axes. Bivariate correlations for the dataset are shown with a color coding as follows: dark red is associated with Spearman correlation coefficient, <italic>R</italic>, equal to 1 and dark blue is associated with <italic>R</italic> = −1. B, Lung cancer–specific immunograms of six patients. The Cancer Genome Atlas (TCGA) case IDs are shown in the panel. C, Immunograms of melanoma patients who received anti‐PD‐1 therapy (cohort of Hugo et al<xref rid="cas14621-bib-0029" ref-type="ref"><sup>29</sup></xref>). Six nonresponders were shown. See also Fig. <xref rid="cas14621-sup-0002" ref-type="supplementary-material">S2</xref>. 1. Innate immunity, 2. Priming &amp; activation, 3. T cells, 4. IFNG response, 5. Inhibitory molecules, 6. Inhibitory cells (Tregs), 7. Inhibitory cells (MDSCs), 8. Recognition of tumor cells, 9. Proliferation, 10. Glycolysis</p>
        </caption>
        <graphic id="nlm-graphic-11" xlink:href="CAS-111-4031-g005"/>
      </fig>
      <p>We analyzed RNA‐Seq data of 28 pretreatment tumors from melanoma patients who received anti‐PD‐1 ICI.<xref rid="cas14621-bib-0029" ref-type="ref"><sup>29</sup></xref> Immunograms were depicted in these pretreatment tumors (Figure <xref rid="cas14621-sup-0002" ref-type="supplementary-material">S2</xref>). Then, we focused on nonresponding (progressive disease) patients (Figure <xref rid="cas14621-fig-0005" ref-type="fig">5C</xref>) and examined whether we could recommend potential combination immunotherapy to these nonresponders using immunogram. The immunograms of Pt10 and Pt12 displayed a typical immunogram pattern of cold tumors. The strategies to induce T cell response in the tumor, for example, cancer vaccine or oncolytic virotherapy, might be recommended to combine with ICI. Besides, glycolysis stood out from the other axes in Pt10. T cell response is hampered by the high energy demand of tumor cells, that is a therapeutic target for combination immunotherapy.<xref rid="cas14621-bib-0035" ref-type="ref"><sup>35</sup></xref> Axis 6 (Treg) and axis 7 (MDSC) were high in Pt25 and Pt16, respectively, suggesting that the strategies to deplete Treg or MDSC might be recommended to these patients. In Pt14 and Pt23, axis 9 (proliferation) was high, suggesting that molecular targeted therapies or chemotherapy that suppress the proliferation of tumor cells might be combined with ICI. While these suggestions necessitate confirmation in a clinical trial, immunogram is considered to be an excellent platform for personalized immuno‐oncology.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="cas14621-sec-0012">
    <label>4</label>
    <title>DISCUSSION</title>
    <p>The concept of the cancer immunogram has attracted a great deal of attention since Blank et al proposed using radar plots as frameworks for describing the diversity of cancer‐immune interactions in each individual patient.<xref rid="cas14621-bib-0026" ref-type="ref"><sup>26</sup></xref> Although their potential value is widely recognized, no versatile scoring method has been developed to construct immunograms in a real‐world setting. Here, we propose a novel scoring method based on RNA‐Seq data and the application of ssGSEA to quantify parameters related to antitumor immunity. We have constructed a web‐accessible database “The RNA‐Seq based Cancer Immunogram Web” (<ext-link ext-link-type="uri" xlink:href="https://yamashige33.shinyapps.io/immunogram/">https://yamashige33.shinyapps.io/immunogram/</ext-link>) with the results of 9362 cancer patients (9417 RNA‐Seq data) from the TCGA cohort.</p>
    <p>Although cancer type–specific immune responses can be appreciated and compared by immunogram analysis (Figure <xref rid="cas14621-fig-0004" ref-type="fig">4</xref>), the real value of using immunograms would be in personalized immuno‐oncology. Indeed, we can easily see that the immunogram patterns differ greatly between patients even with the same type of cancer, reflecting the heterogeneity of immune responses and TME in each individual (Figures <xref rid="cas14621-fig-0003" ref-type="fig">3</xref> and <xref rid="cas14621-fig-0005" ref-type="fig">5</xref>, The RNA‐Seq based Cancer Immunogram Web). As shown in Figure <xref rid="cas14621-fig-0005" ref-type="fig">5B</xref>, for example, the immunogram for TCGA‐86‐8671‐01A suggests pre‐existing T cell responses but tumor‐induced immunosuppressive molecules and cells as counter‐regulators. For these patients, ICI might be expected to be effective. Low scores in priming and activation and high scores for Tregs observed in patient TCGA‐86‐8359‐01A, on the other hand, suggest that combination therapies with DC vaccines and Treg depletion therapy might be recommended. Once we can identify the impaired steps of the antitumor immune response in each patient individually, we might be better able to select some of the several drugs that have already been developed and approved for clinical use in treating certain forms of cancer to overcome these hurdles.<xref rid="cas14621-bib-0036" ref-type="ref"><sup>36</sup></xref> Using immunograms of nonresponding tumors to ICI (Figure <xref rid="cas14621-fig-0005" ref-type="fig">5C</xref>), we could point out the impaired step that might be a potential target for combination therapies in each patient. Immunograms for each individual will be a useful tool for precision immuno‐oncology, although their application needs to be validated in clinical trials.</p>
    <p>Comprehensive assessment and integration of a myriad of potentially immune‐relevant factors is required to generate informative immunograms. To this end, the flexibility of approaches based on RNA‐seq is ideal. RNA‐Seq provides comprehensive transcriptome data,<xref rid="cas14621-bib-0037" ref-type="ref"><sup>37</sup></xref> and ssGSEA scoring provides a useful approach for quantifying selected molecular signatures in the sample transcriptome.<xref rid="cas14621-bib-0030" ref-type="ref"><sup>30</sup></xref> There is a collection of annotated gene sets available for GSEA, such as the Molecular Signatures Database (MSigDB). It is possible to supplement the immunogram with novel relevant biomarkers and easily test different combinations of gene sets by selecting other panels of genes to generate different immunograms. For example, immunograms for hallmarks of cancer could also be compiled by adopting gene sets for the eight hallmarks: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, reprogramming of energy metabolism, and evading immune destruction.<xref rid="cas14621-bib-0038" ref-type="ref"><sup>38</sup></xref>
</p>
    <p>In the present study, we described an immunogram with 10 axes just as an example to introduce our scoring method, but other parameters may need to be considered as well. These 10 parameters have not yet been optimized for developing predictive biomarkers for ICI and for tailoring personalized combination immunotherapy. Accumulating evidence indicates that ICI efficacy is affected by a combination of local and systemic factors involving tumor‐intrinsic, host‐related, and microenvironmental biomarkers. The immunogram described here lacks any data on tumor mutational burden or other genomic data. It also lacks information on systemic factors, environmental factors, and data from immunohistochemistry and flow cytometry. These data can be incorporated into the immunogram; however, methods for normalizing these modalities are set up differently and require considerable labor. We will add these parameters one by one to the immunogram in the future.</p>
    <p>In conclusion, we propose a novel scoring and visualization method for assessing the cancer immunity status of individual patients using the large TCGA dataset and RNA‐Seq of each patient. This study is the first to describe a way of depicting immunograms using real‐world patient data. Immunograms generated in this way are flexible and can incorporate a myriad of gene sets available to the community. Further refinement and validation of such immunograms should contribute to understanding the immunological status of each individual patient for predicting the efficacy of ICI and tailoring optimal combination immunotherapies in a personalized manner.</p>
  </sec>
  <sec sec-type="COI-statement" id="cas14621-sec-0014">
    <title>CONFLICT OF INTEREST</title>
    <p>Dr Kakimi reports grants from TAKARA BIO Inc, grants from MSD, outside the submitted work; the Department of Immunotherapeutics, The University of Tokyo Hospital, is endowed by TAKARA BIO Inc. Dr Yamaguchi is a founder of cBioinformatics. Other authors have no competing interests to disclose.</p>
  </sec>
  <sec id="cas14621-sec-0015">
    <title>ETHICAL CONSIDERATION</title>
    <p>This article does not contain any studies involving human participants performed by any of the authors. The dataset General Research Use in TCGA access as the project titled #12517: "Immunogram for personalized cancer immunotherapy" was approved by NIH (#49374‐7).</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supporting information</title>
    <supplementary-material content-type="local-data" id="cas14621-sup-0001">
      <caption>
        <p>Fig S1</p>
      </caption>
      <media xlink:href="CAS-111-4031-s001.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="cas14621-sup-0002">
      <caption>
        <p>Fig S2</p>
      </caption>
      <media xlink:href="CAS-111-4031-s002.pptx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="cas14621-sup-0003">
      <caption>
        <p>Table S1</p>
      </caption>
      <media xlink:href="CAS-111-4031-s003.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="cas14621-sup-0004">
      <caption>
        <p>Table S2</p>
      </caption>
      <media xlink:href="CAS-111-4031-s004.xlsx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="cas14621-sec-0013">
    <title>ACKNOWLEDGMENTS</title>
    <p>The authors thank Dr Koji Nagaoka, Dr Akihiro Hosoi, Dr Taro Teshima, Ms Mikiko Shibuya, and Ms Jerena Arsenic for technical assistance. This work was conducted with the institutional support of RIKEN. The funder had no role in study design, data collection and analysis, interpretation, decision to publish, preparation of the manuscript, or any aspect of the study.</p>
  </ack>
  <ref-list content-type="cited-references" id="cas14621-bibl-0001">
    <title>REFERENCES</title>
    <ref id="cas14621-bib-0001">
      <label>1</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0001"><string-name><surname>Ribas</surname><given-names>A</given-names></string-name>, <string-name><surname>Wolchok</surname><given-names>JD</given-names></string-name>. <article-title>Cancer immunotherapy using checkpoint blockade</article-title>. <source xml:lang="en">Science</source>. <year>2018</year>;<volume>359</volume>:<fpage>1350</fpage>‐<lpage>1355</lpage>.<pub-id pub-id-type="pmid">29567705</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0002">
      <label>2</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0002"><string-name><surname>Gandhi</surname><given-names>L</given-names></string-name>, <string-name><surname>Rodríguez‐Abreu</surname><given-names>D</given-names></string-name>, <string-name><surname>Gadgeel</surname><given-names>S</given-names></string-name>, et al. <article-title>Pembrolizumab plus chemotherapy in metastatic non–small‐cell lung cancer</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2018</year>;<volume>378</volume>:<fpage>2078</fpage>‐<lpage>2092</lpage>.<pub-id pub-id-type="pmid">29658856</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0003">
      <label>3</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0003"><string-name><surname>Paz‐Ares</surname><given-names>L</given-names></string-name>, <string-name><surname>Luft</surname><given-names>A</given-names></string-name>, <string-name><surname>Vicente</surname><given-names>D</given-names></string-name>, et al. <article-title>Pembrolizumab plus chemotherapy for squamous non–small‐cell lung cancer</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2018</year>;<volume>379</volume>:<fpage>2040</fpage>‐<lpage>2051</lpage>.<pub-id pub-id-type="pmid">30280635</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0004">
      <label>4</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0004"><string-name><surname>Socinski</surname><given-names>MA</given-names></string-name>, <string-name><surname>Jotte</surname><given-names>RM</given-names></string-name>, <string-name><surname>Cappuzzo</surname><given-names>F</given-names></string-name>, et al. <article-title>Atezolizumab for first‐line treatment of metastatic nonsquamous NSCLC</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2018</year>;<volume>378</volume>:<fpage>2288</fpage>‐<lpage>2301</lpage>.<pub-id pub-id-type="pmid">29863955</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0005">
      <label>5</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0005"><string-name><surname>Rini</surname><given-names>BI</given-names></string-name>, <string-name><surname>Plimack</surname><given-names>ER</given-names></string-name>, <string-name><surname>Stus</surname><given-names>V</given-names></string-name>, et al. <article-title>Pembrolizumab plus axitinib versus sunitinib for advanced renal‐cell carcinoma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2019</year>;<volume>380</volume>:<fpage>1116</fpage>‐<lpage>1127</lpage>.<pub-id pub-id-type="pmid">30779529</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0006">
      <label>6</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0006"><string-name><surname>Hodi</surname><given-names>FS</given-names></string-name>, <string-name><surname>Chiarion‐Sileni</surname><given-names>V</given-names></string-name>, <string-name><surname>Gonzalez</surname><given-names>R</given-names></string-name>, et al. <article-title>Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4‐year outcomes of a multicentre, randomised, phase 3 trial</article-title>. <source xml:lang="en">Lancet Oncol</source>. <year>2018</year>;<volume>19</volume>:<fpage>1480</fpage>‐<lpage>1492</lpage>.<pub-id pub-id-type="pmid">30361170</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0007">
      <label>7</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0007"><string-name><surname>Motzer</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Tannir</surname><given-names>NM</given-names></string-name>, <string-name><surname>McDermott</surname><given-names>DF</given-names></string-name>, et al. <article-title>Nivolumab plus ipilimumab versus sunitinib in advanced renal‐cell carcinoma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2018</year>;<volume>378</volume>:<fpage>1277</fpage>‐<lpage>1290</lpage>.<pub-id pub-id-type="pmid">29562145</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0008">
      <label>8</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0008"><string-name><surname>Sharma</surname><given-names>P</given-names></string-name>, <string-name><surname>Hu‐Lieskovan</surname><given-names>S</given-names></string-name>, <string-name><surname>Wargo</surname><given-names>JA</given-names></string-name>, <string-name><surname>Ribas</surname><given-names>A</given-names></string-name>. <article-title>Primary, adaptive, and acquired resistance to cancer immunotherapy</article-title>. <source xml:lang="en">Cell</source>. <year>2017</year>;<volume>168</volume>:<fpage>707</fpage>‐<lpage>723</lpage>.<pub-id pub-id-type="pmid">28187290</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0009">
      <label>9</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0009"><string-name><surname>Havel</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Chowell</surname><given-names>D</given-names></string-name>, <string-name><surname>Chan</surname><given-names>TA</given-names></string-name>. <article-title>The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy</article-title>. <source xml:lang="en">Nat Rev Cancer</source>. <year>2019</year>;<volume>19</volume>:<fpage>133</fpage>‐<lpage>150</lpage>.<pub-id pub-id-type="pmid">30755690</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0010">
      <label>10</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0010"><string-name><surname>Snyder</surname><given-names>A</given-names></string-name>, <string-name><surname>Makarov</surname><given-names>V</given-names></string-name>, <string-name><surname>Merghoub</surname><given-names>T</given-names></string-name>, et al. <article-title>Genetic basis for clinical response to CTLA‐4 blockade in melanoma</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2014</year>;<volume>371</volume>:<fpage>2189</fpage>‐<lpage>2199</lpage>.<pub-id pub-id-type="pmid">25409260</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0011">
      <label>11</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0011"><string-name><surname>Rizvi</surname><given-names>NA</given-names></string-name>, <string-name><surname>Hellmann</surname><given-names>MD</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>A</given-names></string-name>, et al. <article-title>Cancer immunology. Mutational landscape determines sensitivity to PD‐1 blockade in non‐small cell lung cancer</article-title>. <source xml:lang="en">Science</source>. <year>2015</year>;<volume>348</volume>:<fpage>124</fpage>‐<lpage>128</lpage>.<pub-id pub-id-type="pmid">25765070</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0012">
      <label>12</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0012"><string-name><surname>Van Allen</surname><given-names>EM</given-names></string-name>, <string-name><surname>Miao</surname><given-names>D</given-names></string-name>, <string-name><surname>Schilling</surname><given-names>B</given-names></string-name>, et al. <article-title>Genomic correlates of response to CTLA‐4 blockade in metastatic melanoma</article-title>. <source xml:lang="en">Science</source>. <year>2015</year>;<volume>350</volume>:<fpage>207</fpage>‐<lpage>211</lpage>.<pub-id pub-id-type="pmid">26359337</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0013">
      <label>13</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0013"><string-name><surname>Topalian</surname><given-names>SL</given-names></string-name>, <string-name><surname>Taube</surname><given-names>JM</given-names></string-name>, <string-name><surname>Anders</surname><given-names>RA</given-names></string-name>, <string-name><surname>Pardoll</surname><given-names>DM</given-names></string-name>. <article-title>Mechanism‐driven biomarkers to guide immune checkpoint blockade in cancer therapy</article-title>. <source xml:lang="en">Nat Rev Cancer</source>. <year>2016</year>;<volume>16</volume>:<fpage>275</fpage>‐<lpage>287</lpage>.<pub-id pub-id-type="pmid">27079802</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0014">
      <label>14</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0014"><string-name><surname>Gibney</surname><given-names>GT</given-names></string-name>, <string-name><surname>Weiner</surname><given-names>LM</given-names></string-name>, <string-name><surname>Atkins</surname><given-names>MB</given-names></string-name>. <article-title>Predictive biomarkers for checkpoint inhibitor‐based immunotherapy</article-title>. <source xml:lang="en">Lancet Oncol</source>. <year>2016</year>;<volume>17</volume>:<fpage>e542</fpage>‐<lpage>e551</lpage>.<pub-id pub-id-type="pmid">27924752</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0015">
      <label>15</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0015"><string-name><surname>Herbst</surname><given-names>RS</given-names></string-name>, <string-name><surname>Soria</surname><given-names>J‐C</given-names></string-name>, <string-name><surname>Kowanetz</surname><given-names>M</given-names></string-name>, et al. <article-title>Predictive correlates of response to the anti‐PD‐L1 antibody MPDL3280A in cancer patients</article-title>. <source xml:lang="en">Nature</source>. <year>2014</year>;<volume>515</volume>:<fpage>563</fpage>‐<lpage>567</lpage>.<pub-id pub-id-type="pmid">25428504</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0016">
      <label>16</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0016"><string-name><surname>Tumeh</surname><given-names>PC</given-names></string-name>, <string-name><surname>Harview</surname><given-names>CL</given-names></string-name>, <string-name><surname>Yearley</surname><given-names>JH</given-names></string-name>, et al. <article-title>PD‐1 blockade induces responses by inhibiting adaptive immune resistance</article-title>. <source xml:lang="en">Nature</source>. <year>2014</year>;<volume>515</volume>:<fpage>568</fpage>‐<lpage>571</lpage>.<pub-id pub-id-type="pmid">25428505</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0017">
      <label>17</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0017"><string-name><surname>Gao</surname><given-names>J</given-names></string-name>, <string-name><surname>Shi</surname><given-names>LZ</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H</given-names></string-name>, et al. <article-title>Loss of IFN‐gamma pathway genes in tumor cells as a mechanism of resistance to anti‐CTLA‐4 therapy</article-title>. <source xml:lang="en">Cell</source>. <year>2016</year>;<volume>167</volume>:<fpage>397</fpage>‐<lpage>404</lpage>.e399.<pub-id pub-id-type="pmid">27667683</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0018">
      <label>18</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0018"><string-name><surname>Le</surname><given-names>DT</given-names></string-name>, <string-name><surname>Durham</surname><given-names>JN</given-names></string-name>, <string-name><surname>Smith</surname><given-names>KN</given-names></string-name>, et al. <article-title>Mismatch repair deficiency predicts response of solid tumors to PD‐1 blockade</article-title>. <source xml:lang="en">Science</source>. <year>2017</year>;<volume>357</volume>:<fpage>409</fpage>‐<lpage>413</lpage>.<pub-id pub-id-type="pmid">28596308</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0019">
      <label>19</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0019"><string-name><surname>Davoli</surname><given-names>T</given-names></string-name>, <string-name><surname>Uno</surname><given-names>H</given-names></string-name>, <string-name><surname>Wooten</surname><given-names>EC</given-names></string-name>, <string-name><surname>Elledge</surname><given-names>SJ</given-names></string-name>. <article-title>Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy</article-title>. <source xml:lang="en">Science</source>. <year>2017</year>;<volume>355</volume>:<elocation-id>eaaf8399</elocation-id>.<pub-id pub-id-type="pmid">28104840</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0020">
      <label>20</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0020"><string-name><surname>Chowell</surname><given-names>D</given-names></string-name>, <string-name><surname>Morris</surname><given-names>LGT</given-names></string-name>, <string-name><surname>Grigg</surname><given-names>CM</given-names></string-name>, et al. <article-title>Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy</article-title>. <source xml:lang="en">Science</source>. <year>2018</year>;<volume>359</volume>:<fpage>582</fpage>‐<lpage>587</lpage>.<pub-id pub-id-type="pmid">29217585</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0021">
      <label>21</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0021"><string-name><surname>Riaz</surname><given-names>N</given-names></string-name>, <string-name><surname>Havel</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Makarov</surname><given-names>V</given-names></string-name>, et al. <article-title>Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab</article-title>. <source xml:lang="en">Cell</source>. <year>2017</year>;<volume>171</volume>(<issue>4</issue>):<fpage>934</fpage>‐<lpage>949.</lpage><pub-id pub-id-type="pmid">29033130</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0022">
      <label>22</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0022"><string-name><surname>Spranger</surname><given-names>S</given-names></string-name>, <string-name><surname>Bao</surname><given-names>R</given-names></string-name>, <string-name><surname>Gajewski</surname><given-names>TF</given-names></string-name>. <article-title>Melanoma‐intrinsic beta‐catenin signalling prevents anti‐tumour immunity</article-title>. <source xml:lang="en">Nature</source>. <year>2015</year>;<volume>523</volume>:<fpage>231</fpage>‐<lpage>235</lpage>.<pub-id pub-id-type="pmid">25970248</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0023">
      <label>23</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0023"><string-name><surname>Mariathasan</surname><given-names>S</given-names></string-name>, <string-name><surname>Turley</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Nickles</surname><given-names>D</given-names></string-name>, et al. <article-title>TGFbeta attenuates tumour response to PD‐L1 blockade by contributing to exclusion of T cells</article-title>. <source xml:lang="en">Nature</source>. <year>2018</year>;<volume>554</volume>:<fpage>544</fpage>‐<lpage>548</lpage>.<pub-id pub-id-type="pmid">29443960</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0024">
      <label>24</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0024"><string-name><surname>Chaput</surname><given-names>N</given-names></string-name>, <string-name><surname>Lepage</surname><given-names>P</given-names></string-name>, <string-name><surname>Coutzac</surname><given-names>C</given-names></string-name>, et al. <article-title>Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab</article-title>. <source xml:lang="en">Ann Oncol</source>. <year>2017</year>;<volume>28</volume>:<fpage>1368</fpage>‐<lpage>1379</lpage>.<pub-id pub-id-type="pmid">28368458</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0025">
      <label>25</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0025"><string-name><surname>Binnewies</surname><given-names>M</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>EW</given-names></string-name>, <string-name><surname>Kersten</surname><given-names>K</given-names></string-name>, et al. <article-title>Understanding the tumor immune microenvironment (TIME) for effective therapy</article-title>. <source xml:lang="en">Nat Med</source>. <year>2018</year>;<volume>24</volume>:<fpage>541</fpage>‐<lpage>550</lpage>.<pub-id pub-id-type="pmid">29686425</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0026">
      <label>26</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0026"><string-name><surname>Blank</surname><given-names>CU</given-names></string-name>, <string-name><surname>Haanen</surname><given-names>JB</given-names></string-name>, <string-name><surname>Ribas</surname><given-names>A</given-names></string-name>, <string-name><surname>Schumacher</surname><given-names>TN</given-names></string-name>. <article-title>The “cancer immunogram”</article-title>. <source xml:lang="en">Science</source>. <year>2016</year>;<volume>352</volume>:<fpage>658</fpage>‐<lpage>660</lpage>.<pub-id pub-id-type="pmid">27151852</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0027">
      <label>27</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0027"><string-name><surname>Karasaki</surname><given-names>T</given-names></string-name>, <string-name><surname>Nagayama</surname><given-names>K</given-names></string-name>, <string-name><surname>Kuwano</surname><given-names>H</given-names></string-name>, et al. <article-title>An immunogram for the cancer‐immunity cycle: towards personalized immunotherapy of lung cancer</article-title>. <source xml:lang="en">J Thorac Oncol</source>. <year>2017</year>;<volume>12</volume>:<fpage>791</fpage>‐<lpage>803</lpage>.<pub-id pub-id-type="pmid">28088513</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0028">
      <label>28</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0028"><string-name><surname>van Dijk</surname><given-names>N</given-names></string-name>, <string-name><surname>Funt</surname><given-names>SA</given-names></string-name>, <string-name><surname>Blank</surname><given-names>CU</given-names></string-name>, <string-name><surname>Powles</surname><given-names>T</given-names></string-name>, <string-name><surname>Rosenberg</surname><given-names>JE</given-names></string-name>, <string-name><surname>van der Heijden</surname><given-names>MS</given-names></string-name>. <article-title>The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer</article-title>. <source xml:lang="en">Eur Urol</source>. <year>2019</year>;<volume>75</volume>:<fpage>435</fpage>‐<lpage>444</lpage>.<pub-id pub-id-type="pmid">30274701</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0029">
      <label>29</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0029"><string-name><surname>Hugo</surname><given-names>W</given-names></string-name>, <string-name><surname>Zaretsky</surname><given-names>JM</given-names></string-name>, <string-name><surname>Sun</surname><given-names>LU</given-names></string-name>, et al. <article-title>Genomic and transcriptomic features of response to anti‐PD‐1 therapy in metastatic melanoma</article-title>. <source xml:lang="en">Cell</source>. <year>2016</year>;<volume>165</volume>:<fpage>35</fpage>‐<lpage>44</lpage>.<pub-id pub-id-type="pmid">26997480</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0030">
      <label>30</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0030"><string-name><surname>Barbie</surname><given-names>DA</given-names></string-name>, <string-name><surname>Tamayo</surname><given-names>P</given-names></string-name>, <string-name><surname>Boehm</surname><given-names>JS</given-names></string-name>, et al. <article-title>Systematic RNA interference reveals that oncogenic KRAS‐driven cancers require TBK1</article-title>. <source xml:lang="en">Nature</source>. <year>2009</year>;<volume>462</volume>:<fpage>108</fpage>‐<lpage>112</lpage>.<pub-id pub-id-type="pmid">19847166</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0031">
      <label>31</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0031"><string-name><surname>Newman</surname><given-names>AM</given-names></string-name>, <string-name><surname>Liu</surname><given-names>CL</given-names></string-name>, <string-name><surname>Green</surname><given-names>MR</given-names></string-name>, et al. <article-title>Robust enumeration of cell subsets from tissue expression profiles</article-title>. <source xml:lang="en">Nat Methods</source>. <year>2015</year>;<volume>12</volume>:<fpage>453</fpage>‐<lpage>457</lpage>.<pub-id pub-id-type="pmid">25822800</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0032">
      <label>32</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0032"><string-name><surname>Laurent</surname><given-names>C</given-names></string-name>, <string-name><surname>Charmpi</surname><given-names>K</given-names></string-name>, <string-name><surname>Gravelle</surname><given-names>P</given-names></string-name>, et al. <article-title>Several immune escape patterns in non‐Hodgkin's lymphomas</article-title>. <source xml:lang="en">Oncoimmunology</source>. <year>2015</year>;<volume>4</volume>:<elocation-id>e1026530</elocation-id>.<pub-id pub-id-type="pmid">26405585</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0033">
      <label>33</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0033"><string-name><surname>Angelova</surname><given-names>M</given-names></string-name>, <string-name><surname>Charoentong</surname><given-names>P</given-names></string-name>, <string-name><surname>Hackl</surname><given-names>H</given-names></string-name>, et al. <article-title>Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy</article-title>. <source xml:lang="en">Genome Biol</source>. <year>2015</year>;<volume>16</volume>:<fpage>64</fpage>.<pub-id pub-id-type="pmid">25853550</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0034">
      <label>34</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0034"><string-name><surname>Şenbabaoğlu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Gejman</surname><given-names>RS</given-names></string-name>, <string-name><surname>Winer</surname><given-names>AG</given-names></string-name>, et al. <article-title>Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures</article-title>. <source xml:lang="en">Genome Biol</source>. <year>2016</year>;<volume>17</volume>:<fpage>231</fpage>.<pub-id pub-id-type="pmid">27855702</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0035">
      <label>35</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0035"><string-name><surname>Kishton</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Sukumar</surname><given-names>M</given-names></string-name>, <string-name><surname>Restifo</surname><given-names>NP</given-names></string-name>. <article-title>Metabolic regulation of T cell longevity and function in tumor immunotherapy</article-title>. <source xml:lang="en">Cell Metab</source>. <year>2017</year>;<volume>26</volume>:<fpage>94</fpage>‐<lpage>109</lpage>.<pub-id pub-id-type="pmid">28683298</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0036">
      <label>36</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0036"><string-name><surname>Patel</surname><given-names>SA</given-names></string-name>, <string-name><surname>Minn</surname><given-names>AJ</given-names></string-name>. <article-title>Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies</article-title>. <source xml:lang="en">Immunity</source>. <year>2018</year>;<volume>48</volume>:<fpage>417</fpage>‐<lpage>433</lpage>.<pub-id pub-id-type="pmid">29562193</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0037">
      <label>37</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0037"><string-name><surname>Nagalakshmi</surname><given-names>U</given-names></string-name>, <string-name><surname>Waern</surname><given-names>K</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>M</given-names></string-name>. <article-title>RNA‐Seq: a method for comprehensive transcriptome analysis</article-title>. <source xml:lang="en">Curr Protoc Mol Biol</source>. <year>2010</year>;<volume>Chapter 4</volume>:<fpage>Unit 4.11.11‐13</fpage>.</mixed-citation>
    </ref>
    <ref id="cas14621-bib-0038">
      <label>38</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0038"><string-name><surname>Pavlova</surname><given-names>NN</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>CB</given-names></string-name>. <article-title>The emerging hallmarks of cancer metabolism</article-title>. <source xml:lang="en">Cell Metab</source>. <year>2016</year>;<volume>23</volume>:<fpage>27</fpage>‐<lpage>47</lpage>.<pub-id pub-id-type="pmid">26771115</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0039">
      <label>39</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0039"><string-name><surname>Abbas</surname><given-names>AR</given-names></string-name>, <string-name><surname>Baldwin</surname><given-names>D</given-names></string-name>, <string-name><surname>Ma</surname><given-names>Y</given-names></string-name>, et al. <article-title>Immune response in silico (IRIS): immune‐specific genes identified from a compendium of microarray expression data</article-title>. <source xml:lang="en">Genes Immun</source>. <year>2005</year>;<volume>6</volume>:<fpage>319</fpage>‐<lpage>331</lpage>.<pub-id pub-id-type="pmid">15789058</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0040">
      <label>40</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0040"><string-name><surname>Becht</surname><given-names>E</given-names></string-name>, <string-name><surname>Giraldo</surname><given-names>NA</given-names></string-name>, <string-name><surname>Lacroix</surname><given-names>L</given-names></string-name>, et al. <article-title>Estimating the population abundance of tissue‐infiltrating immune and stromal cell populations using gene expression</article-title>. <source xml:lang="en">Genome Biol</source>. <year>2016</year>;<volume>17</volume>:<fpage>218</fpage>.<pub-id pub-id-type="pmid">27765066</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0041">
      <label>41</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0041"><string-name><surname>Cursons</surname><given-names>J</given-names></string-name>, <string-name><surname>Souza‐Fonseca‐Guimaraes</surname><given-names>F</given-names></string-name>, <string-name><surname>Foroutan</surname><given-names>M</given-names></string-name>, et al. <article-title>A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients</article-title>. <source xml:lang="en">Cancer Immunol Res</source>. <year>2019</year>;<volume>7</volume>:<fpage>1162</fpage>‐<lpage>1174</lpage>.<pub-id pub-id-type="pmid">31088844</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0042">
      <label>42</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0042"><string-name><surname>Nirmal</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Regan</surname><given-names>T</given-names></string-name>, <string-name><surname>Shih</surname><given-names>BB</given-names></string-name>, <string-name><surname>Hume</surname><given-names>DA</given-names></string-name>, <string-name><surname>Sims</surname><given-names>AH</given-names></string-name>, <string-name><surname>Freeman</surname><given-names>TC</given-names></string-name>. <article-title>Immune cell gene signatures for profiling the microenvironment of solid tumors</article-title>. <source xml:lang="en">Cancer Immunol Res</source>. <year>2018</year>;<volume>6</volume>:<fpage>1388</fpage>‐<lpage>1400</lpage>.<pub-id pub-id-type="pmid">30266715</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0043">
      <label>43</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0043"><string-name><surname>Tosolini</surname><given-names>M</given-names></string-name>, <string-name><surname>Pont</surname><given-names>F</given-names></string-name>, <string-name><surname>Poupot</surname><given-names>M</given-names></string-name>, et al. <article-title>Assessment of tumor‐infiltrating TCRVgamma9Vdelta2 gammadelta lymphocyte abundance by deconvolution of human cancers microarrays</article-title>. <source xml:lang="en">Oncoimmunology</source>. <year>2017</year>;<volume>6</volume>:<elocation-id>e1284723</elocation-id>.<pub-id pub-id-type="pmid">28405516</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0044">
      <label>44</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0044"><string-name><surname>Charoentong</surname><given-names>P</given-names></string-name>, <string-name><surname>Finotello</surname><given-names>F</given-names></string-name>, <string-name><surname>Angelova</surname><given-names>M</given-names></string-name>, et al. <article-title>Pan‐cancer immunogenomic analyses reveal genotype‐immunophenotype relationships and predictors of response to checkpoint blockade</article-title>. <source xml:lang="en">Cell Rep</source>. <year>2017</year>;<volume>18</volume>:<fpage>248</fpage>‐<lpage>262</lpage>.<pub-id pub-id-type="pmid">28052254</pub-id></mixed-citation>
    </ref>
    <ref id="cas14621-bib-0045">
      <label>45</label>
      <mixed-citation publication-type="journal" id="cas14621-cit-0045"><string-name><surname>Schelker</surname><given-names>M</given-names></string-name>, <string-name><surname>Feau</surname><given-names>S</given-names></string-name>, <string-name><surname>Du</surname><given-names>J</given-names></string-name>, et al. <article-title>Estimation of immune cell content in tumour tissue using single‐cell RNA‐seq data</article-title>. <source xml:lang="en">Nat Commun</source>. <year>2017</year>;<volume>8</volume>:<fpage>2032</fpage>.<pub-id pub-id-type="pmid">29230012</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
